The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
Frontiers in Oncology,
Год журнала:
2022,
Номер
12
Опубликована: Авг. 23, 2022
The
emergence
of
checkpoint
inhibitors
has
created
a
paradigm
shift
for
the
treatment
various
malignancies.
However,
although
these
therapies
are
associated
with
improved
survival
rates,
they
also
carry
risk
immune-related
adverse
events
(irAEs).
Moderate
to
severe
irAEs
typically
treated
glucocorticoids,
sometimes
addition
immunosuppressants
as
steroid-sparing
therapy.
it
is
unclear
how
glucocorticoids
and
may
impact
cancer
efficacy
immune
therapy
on
cancer.
In
this
narrative
review,
we
discuss
effects
including
methotrexate,
hydroxychloroquine,
azathioprine,
mycophenolate
mofetil,
tumor-necrosis
factor
(TNF)-inhibitors,
interleukin-6
inhibitors,
interleukin-1
abatacept,
rituximab,
Janus
kinase
(JAKi)
cancer-specific
outcomes
in
setting
inhibitor
use.
Язык: Английский
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Янв. 26, 2023
Checkpoint
inhibitors
(CPIs)
are
monoclonal
antibodies
which,
by
disrupting
interactions
of
immune
checkpoint
molecules
with
their
ligands,
block
regulatory
signals
otherwise
exploited
cancers.
Despite
revolutionary
clinical
benefits,
CPI
use
is
associated
an
array
immune-related
adverse
events
(irAEs)
that
mirror
spontaneous
autoreactivity.
Severe
irAEs
necessitate
pausing
or
stopping
therapy
and
corticosteroids
and/or
other
immunomodulatory
interventions.
increasingly
widespread
use,
irAE
pathobiology
remains
poorly
understood;
its
elucidation
may
point
to
targeted
mitigation
strategies
uncover
predictive
biomarkers
for
onset
in
patients,
whilst
casting
new
light
on
mechanisms
immune-mediated
disease.
This
review
focuses
common
CPI-induced
the
gut,
skin
synovial
joints,
how
these
compare
diseases
such
as
ulcerative
colitis,
vitiligo
inflammatory
arthritis.
We
current
understanding
immunological
changes
reported
following
at
level
peripheral
blood
tissue.
Many
studies
highlight
dysregulation
cytokines
irAE-affected
tissue,
particularly
IFNγ
TNF.
IrAE-affected
tissues
also
predominantly
infiltrated
T-cells,
low
B-cell
infiltration.
Whilst
there
variability
between
studies,
patients
treated
anti-programmed
cell
death-1
(PD-1)/PDL-1
therapies
seem
exhibit
CD8+
T-cell
dominance,
CD4+
T-cells
dominating
those
anti-cytotoxic
T-lymphocyte-associated
protein
4
(CTLA-4)
monotherapy.
Interestingly,
CD8+CXCR3+
have
been
be
elevated
gastrointestinal,
dermatological
musculoskeletal
-irAE
affected
tissues.
These
findings
potential
opportunities
therapeutic
development
re-deployment
existing
prevent
improve
outcome
irAEs.
Язык: Английский
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
American Journal of Clinical Dermatology,
Год журнала:
2024,
Номер
25(4), С. 595 - 607
Опубликована: Май 20, 2024
Язык: Английский
Immune Checkpoint Inhibitor-Induced Psoriasis
Dermatologic Clinics,
Год журнала:
2024,
Номер
42(3), С. 481 - 493
Опубликована: Март 15, 2024
Язык: Английский
A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution
Cancer Treatment and Research Communications,
Год журнала:
2022,
Номер
30, С. 100506 - 100506
Опубликована: Янв. 1, 2022
Immune
checkpoint
inhibitors
and
their
associated
immune-related
cutaneous
adverse
events
are
continuing
to
become
a
mainstay
of
cancer
treatment
regimens.
While
most
rashes
mild
easily
manageable,
severe
or
persistent
like
lichenoid
dermatoses
can
significantly
impact
the
quality
life
may
require
ICI
cessation.
Lichenoid
currently
have
no
management
guidelines
beyond
use
topical
oral
steroids.
Our
study
is
single-institution
retrospective
chart
review
characterize
ICI-induced
eruptions,
treatments,
tumor
response.
We
utilized
natural
language
processing
our
institutional
medical
record
identify
patients
with
eruptions
on
therapy.
One-hundred
nineteen
were
identified,
which
108
characterized
as
dermatitis
fifteen
mucositis.
Most
presented
diffuse
distribution
(86%,
101/117),
pruritus
in
(82%,
89/108)
pain
mucositis
(80%,
12/15).
Successful
treatments
for
included
steroids
(81%,
88/108),
antihistamines
(21%,
23/108),
(15%,
16/108).
Of
patients,
21%
(23/108)
did
not
respond
(7)
required
(16).
Approximately
28%
who
had
delay,
reduction,
discontinuation
because
irCAE.
This
descriptive
highlights
patients'
ability
remain
therapy
need
more
effective
non-steroidal
strategies.
Язык: Английский
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
Cureus,
Год журнала:
2023,
Номер
unknown
Опубликована: Авг. 9, 2023
The
increasing
use
of
immune
checkpoint
inhibitors,
such
as
nivolumab,
a
programmed
cell
death
protein
1
(PD-1)
inhibitor,
for
advanced
neoplastic
disease
has
revealed
significant
cutaneous
immune-related
adverse
effects.
Herein,
we
report
case
bullous
pemphigoid
(BP)
secondary
to
nivolumab
therapy
recurrent
metastatic
oropharyngeal
squamous
carcinoma.
In
this
patient,
the
time
development
BP
was
three
years,
which
represents
most
delayed
onset
PD-1
inhibitor
that
been
reported
in
literature.
Symptoms
were
initially
controlled
on
low-dose
oral
prednisone
but
recurred
after
two
years.
patient
subsequently
treated
with
several-month
taper
high-dose
prednisone,
during
he
able
resume
without
recurrence
skin
lesions.
Although
inhibitor-induced
remains
rare,
physicians
should
be
aware
serious
event
drug
class
continues
expand.
Язык: Английский
Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Дек. 5, 2024
Checkpoint
inhibitors
are
increasingly
important
in
anti-cancer
treatment.
Therefore,
knowledge
of
immune-related
cutaneous
adverse
events
(ir-cAE)
is
crucial
for
therapy
management
and
continuation.
Язык: Английский
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Critical Reviews in Immunology,
Год журнала:
2022,
Номер
42(4), С. 1 - 20
Опубликована: Янв. 1, 2022
Immune
checkpoint
inhibitors
(CPIs)
are
highly
effective
in
the
treatment
of
various
cancers.
Immunotherapy
enhances
antitumor
activity
by
relieving
inhibition
T
cells
responsible
for
immune
surveillance.
However,
overactivation
leads
to
immune-related
adverse
events
(irAE),
which
cutaneous
most
common.
Examples
include
pruritus
and
maculopapular
eruption
commonly,
psoriasis
bullous
dermatoses
less
and,
rarely,
severe,
life-threatening
eruptions
such
as
Stevens-Johnson
Syndrome
or
Toxic
Epidermal
Necrolysis.
Many
these
autoimmune
nature,
may
present
<i>de
novo</i>
recurrence
pre-existing
disease.
In
order
maximize
therapeutic
potential
CPIs,
it
is
essential
recognize
effectively
manage
irAE,
can
otherwise
lead
interruption
discontinuation.
This
review
summarizes
presentation
management
dermatologic
secondary
dysregulation
a
result
inhibitor
therapy,
including
common
(maculopapular
eruption,
pruritus,
lichenoid
dermatitis,
vitiligo),
(psoriasis,
pemphigoid,
erythema
multiforme,
eczematous
alopecia
areata,
granulo-matous
neutrophilic
dermatoses),
severe
(acute
generalized
exanthematous
pustulosis
[AGEP],
drug
reaction
with
eosinophilia
systemic
symptoms
[DRESS],
syndrome
toxic
epidermal
necrolysis
[SJS/TEN]),
well
exacerbation
disease
(subacute
lupus
erythematosus,
dermatomyositis,
eosinophilic
fasciitis,
leukocytoclastic
vasculitis,
scleroderma-like
reaction).
Язык: Английский